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Searching for Bacteria in Neural
Tissue From Amyotrophic
Lateral Sclerosis
Ruth Alonso†, Diana Pisa† and Luis Carrasco*
Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain
Despite great efforts in the investigation, the exact etiology of amyotrophic lateral
sclerosis (ALS) is a matter of intensive research. We recently advanced the idea that ALS
might be caused by fungal infection. Indeed, fungal yeast and hyphal structures can be
directly visualized in neural tissue of ALS patients, and a number of fungal species have
been identified in the central nervous system (CNS). In the present work, we tested
the possibility that bacterial infections can accompany these mycoses. Our findings
establish the presence of bacterial DNA in different regions of the CNS from all ALS
patients examined. Specifically, we used PCR and next generation sequencing (NGS) to
precisely determine the bacterial species present in ALS tissue. Consistent with these
findings, immunohistochemistry analysis of CNS sections using specific anti-bacterial
antibodies identified prokaryotic cells in neural tissue. Finally, we assayed for the repeat
expansion of the hexanucleotide repeat GGGGCC in C9orf72, which is considered the
most common genetic cause of ALS in patients, using DNA extracted from ALS CNS
tissue. We failed to find this repeated sequence in any of the eleven patients analyzed.
Our results indicate that bacterial DNA and prokaryotic cells are present in CNS tissue,
leading to the concept that both fungal and bacterial infections coexist in patients with
ALS. These observations lay the groundwork for the use of appropriate therapies to
eradicate the polymicrobial infections in ALS.
Keywords: neurodegenerative disease, amyotrophic lateral sclerosis, polymicrobial infection, next generation
sequencing, repeat expansion C9orf72
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common of the motor neuron diseases and is
characterized by progressive muscular dystrophy and degeneration of motor neurons, ultimately
leading to fatal paralysis in adulthood (Saberi et al., 2015; Huynh et al., 2016; Oskarsson et al., 2018).
Whereas most cases of ALS are classified as sporadic, about 5% are familial forms and have a genetic
basis (Iguchi et al., 2013). Typically, ALS has a focal presentation with a progressive and selective
loss of both cortical (upper) and spinal (lower) motor neurons across multiple body regions (Ravits
and La Spada, 2009; Turner et al., 2013). ALS has been related to other neurodegenerative diseases
such as frontotemporal dementia (FTD), and the boundaries between these disorders are not
clear. A number of modifications in neurons of the frontal cortex, temporal cortex, hippocampus,
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cerebellum and striatum have been identified in ALS (Saberi
et al., 2015) and, as a consequence, cognitive and behavioral
impairment are recognized in 30% of cases and 14% also have
FTD (Turner et al., 2013).
Despite extensive research, the etiology of ALS remains
uncertain. Two major avenues of research have been followed
in an attempt to uncover the origin of ALS: characterization of
the cytoplasmic granules found in some motor neurons, and
identification of genetic mutations in patients with ALS. As
occurs in many neurodegenerative syndromes, several proteins
have been found to form cytoplasmic aggregates in affected brain
regions in the majority of patients. This is exemplified by the
presence of ubiquitinated inclusions, some of them containing
transactive response-DNA binding protein 43 (TDP-43), and
others occasionally containing the protein fused in sarcoma
(FUS) (Saberi et al., 2015; Huynh et al., 2016). These proteins
are predominantly nuclear, shuttling between the nucleus and
cytoplasm (Wang et al., 2004; Lagier-Tourenne et al., 2010) and,
under abnormal conditions, they accumulate in the cytoplasm
forming a component of stress granules (Fan and Leung, 2016).
Besides TDP-43 and FUS, many additional proteins are under
investigation as potential participants in ALS pathogenesis,
including heterogeneous nuclear ribonucleoprotein A1
(hnRNPA1), hnRNPA2B1, hnRNPA3, TAF15, and EWSR1
(Neumann et al., 2011; Ugras and Shorter, 2012; Thomsen et al.,
2013; Le Ber et al., 2014).
A number of mutations in over 25 genes have been described
thus far in familial ALS (Corcia et al., 2017), confirming that
the genetic background may predispose to ALS and pointing
to the participation of a range of genes in the pathology of
the disease. Mutations in the gene encoding Cu/Zn-superoxide
dismutase (SOD1) were the first to be linked to ALS in patients
and remain the most prevalent. Later studies uncovered many
others, such as FUS, TARDBP, and TBK1 (Leblond et al., 2014;
Renton et al., 2014; Tan et al., 2017). More recently, a large
hexanucleotide (GGGGCC) repeat expansion in the first intron
of the C9orf72 gene (Renton et al., 2014; Herrmann and Parlato,
2018) was identified to account for 35% of familial ALS patients
and for ∼5–7% of sporadic cases of European ancestry, whereas
it was relatively absent in Asian ALS patients (Majounie et al.,
2012; Woollacott and Mead, 2014; Muller et al., 2018). The
C9orf72 gene contains twelve exons, with three transcription
variants that synthesize two protein isoforms, termed a and
b (De Jesus-Hernandez et al., 2011; Renton et al., 2011). The
encoded protein is a Rab guanine exchange factor involved in
membrane trafficking and autophagy (Levine et al., 2013; Sellier
et al., 2016; Webster et al., 2016). Three different mechanisms
have been suggested to account for the neuropathology linked to
this repeated expansion. One mechanism is the down regulation
of C9orf72 gene expression (De Jesus-Hernandez et al., 2011) and
the second entails a gain-of-function by sequestration of essential
RNA-binding proteins (RBPs) into intranuclear RNA foci via
their interaction with the tandem repeat expansion in the mRNA
(Gendron et al., 2014; Ciesiolka et al., 2017). Indeed, a variety
of RBPs can interact with the repeated expansion, particularly
proteins belonging to the hnRNP family (Kumar and Ghosh,
2017). A third mechanism involves the formation of aberrant
spliced mRNAs bearing the repeat expansion, which can lead
to the synthesis of proteins containing dipeptide repeats (DPRs)
(Gendron et al., 2013; Tabet et al., 2018). Translation of both sense
and anti-sense aberrant C9orf72 mRNAs has been proposed,
beginning translation at a CUG codon. This repeat-associated
non-AUG translation may lead to the synthesis of a variety of
proteins bearing different DPRs, which could associate to form
granules involved in cytotoxicity (Kumar and Ghosh, 2017).
These three mechanisms are not mutually exclusive and may
occur simultaneously (Todd and Petrucelli, 2016), however, only
a small percentage of mRNAs in which intron retention occurs
contain the repeat expansion. Moreover, since this expansion is
in the 5′ untranslated region, translation of this expanded repeat
should be very inefficient.
Thus, a central idea in ALS research is that mutated proteins
forming after an undefined stress aggregate in granules that
become pathological for the correct functioning of motor
neurons (Iguchi et al., 2013; Saberi et al., 2015; Huynh et al.,
2016). The aggregates might be a consequence of the impairment
of protein transport between the nucleus and cytoplasm in the
case of TDP-43 or of the synthesis of aberrant proteins containing
DPRs (Jovicic et al., 2016; Prpar Mihevc et al., 2017).
We have recently advanced the idea that ALS may be caused
by fungal infection (Alonso et al., 2015, 2017b). In this respect,
the different mutated genes described in ALS may reflect a
genetic susceptibility for infection. Several lines of investigation
support the concept that microbial infection occurs in the CNS
of ALS patients. The most direct evidence is the demonstration
of fungal yeast and hyphal structures in neural tissue from ALS
patients (Alonso et al., 2017b), and the identification of different
fungal species in different CNS regions by next generation
sequencing (NGS). Another line of evidence in support of the
infectious etiology of ALS comes from the finding that amyloid
peptide exhibits strong antifungal and antibacterial activity and
is involved in the innate immune response (Soscia et al., 2010;
Kumar et al., 2016). ALS patients contain amyloid plaques in the
CNS, as occurs with other neurodegenerative diseases (Schmidt
et al., 1998; Farid et al., 2015; Takeda, 2018). Finally, high
levels of chitotriosidase (chitinase) have been detected in the
cerebrospinal fluid (CSF) of patients with ALS (Varghese et al.,
2013a; Pagliardini et al., 2015). This enzyme is synthesized in
response to its substrate, chitin, which is a component of the
fungal cell wall. These experimental findings cannot be explained
simply by the hypothesis that mutations in some genes are the
cause of ALS, but they are compatible with the idea that ALS is
provoked by disseminated mycoses.
In the present work, we have examined the possibility
that bacterial infections accompany these mycoses. Our results
support the existence of polymicrobial infections in the CNS
of ALS patients.
MATERIALS AND METHODS
Description of ALS Patients
CNS sections and frozen tissue were obtained from 11 patients
diagnosed with ALS. The age, gender and code number
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of each patient are indicated (Supplementary Table 1). All
ALS cases studied In this work were sporadic. In addition
to ALS, patient 1 was diagnosed with FTD and patient 8
was diagnosed with hippocampal sclerosis. All samples were
supplied by the Banco de Tejidos CIEN, Madrid, brain bank
and were analyzed anonymously. Sample transfer was carried
out according to national regulations concerning research on
human biological samples and written informed consent was
obtained in all cases. The ethics committee of the Universidad
Autónoma de Madrid approved the study. All samples were
processed according to a common postmortem protocol followed
by Banco de Tejidos CIEN. To avoid contamination, the
frozen tissue was handled with sterile instruments in a
laminar flow hood.
DNA Extraction From CNS
Tissue and Nested PCR
DNA was extracted from frozen samples as described (Alonso
et al., 2017a). To assay for bacterial DNA, we used nested PCR
with several primer pairs as described (Alonso et al., 2017a),
which amplify a region between the V3–V4 variable region of the
prokaryotic 16S rRNA gene. In the first PCR, 4 µl of DNA was
denatured at 95◦C for 5 min, followed by 35 cycles of 1 min at
94◦C, 1 min at 56◦C and 3 min at 72◦C, using primers 27F and
1492R. The second PCR was performed using 2 µl of the product
obtained in the first PCR with forward V3 and reverse V4 internal
primers, for 30 cycles of 1 min at 94◦C, 1 min at 55◦C and 3 min
at 72◦C (Supplementary Figure 1).
In addition, the intergenic spacer (IGS) region between rRNA
genes of the prokaryotic genome was amplified using the primers
1406(F)/559(R) and 1492(F)/242(R) in the first and second round
PCR, respectively (see scheme in Figure 1A). The first PCR was
carried out with 4 µl of DNA denatured at 95◦C for 5 min,
followed by 45 cycles of 1 min at 94◦C, 1 min at 55◦C and
3 min at 72◦C. The second PCR was performed using 2 µl of
the product obtained in the first PCR, for 35 cycles of 1 min at
94◦C, 1 min at 57◦C and 3 min at 72◦C. Some PCR products
were sequenced by Macrogen Inc. (Seoul, Korea). The sequences
have been submitted to the European Nucleotide Archive with
the access numbers LR031262–LR031290.
To analyze the hexanucleotide expansion repeat in the
C9orf72 gene in the different samples, we performed PCR with
4µl of DNA denatured at 95◦C for 5 min, followed by 45 cycles of
1 min at 94◦C, 1 min at 56◦C and 3 min at 72◦C. The primers used
were (F): 5′AGTCGCTAGAGGCGAAAGC3′ and (R): 5′TAC
GCATCCCAGTTTGAGACG CGGGGGCCGGGGCCGGGGC
CGGGG 3′.
Next Generation Sequencing
NGS was performed as described (Alonso et al., 2017a), and
primers were designed to amplify the region between the variable
V3–V4 16S rDNA gene. Primers were joined to linker sequences
in a first round of PCR (specific product of ∼400 nucleotides).
A second PCR was performed on the products using fusion
primers containing Illumina and linker sequences. PCR products
were sequenced on a MiSeq sequencing platform (Illumina).
PCR and sequencing were carried out by the Genomics Unit
at the Scientific Park of Madrid. Quality analyses were carried
out over reads using FastQC software1. All sequences have
been submitted to European Genome-phenome Archive with the
accession numbers EGAR00001825350–EGAR00001825307.
Computational Analysis
Qiime Analysis
We used QIIME software for metagenomic analysis of bacteria
(Caporaso et al., 2010), which is an open-source bioinformatics
pipeline for microbiome analysis from raw DNA sequencing
data. QIIME is designed to take users from raw sequencing
data to publication-quality graphics and statistics. This includes
demultiplexing and quality filtering, operational taxonomic
unit (OTU) picking, taxonomic assignment and phylogenetic
reconstruction, and diversity analyses and visualizations. The
adapters from the sequences were deleted using Cutadapt and
all sequences with a length shorter than 35 base pairs were
discarded. Once sequence set-up was ready, we performed a
metagenomic-type analysis that consisted of several steps.
Sequence Clustering
The sequences were grouped to define OTUs as reported (Alonso
et al., 2018) with a percentage identity of 94%.
Principal Component Analysis
Principal component analysis (PCA) was carried out as reported
(Alonso et al., 2018).
Statistical Analysis
Statistical analysis was performed using the nonparametric
Wilconxon–Mann–Whitney test to calculate pairwise compari-
sons between group levels with corrections for multiple testing.
Statistical analyses of species and genera was performed using the
Statistical Analysis of Metagenomic Profiles (STAMP) software
package (Parks et al., 2014).
Immunohistochemistry Analysis
The antifungal antibodies employed have been described
previously (Pisa et al., 2015, 2016a). The following bacterial
antibodies were used: rabbit polyclonal antibody against
Chlamydophila pneumoniae, which immunoreacts with the
major outer porin (Biorbyt, Cambridge, United Kingdom),
used at 1:20 dilution; and mouse monoclonal antibody against
peptidoglycan (Thermo Fisher Scientific, Waltham, MA,
United States), used at 1:20 dilution. Standard techniques
were used for paraffin embedding and sectioning of CNS
tissue. Protocols for immunohistochemical analysis have
been described (Pisa et al., 2016b). Most of the images were
obtained with a Zeiss LSM710 multiphoton confocal laser
scanning microscope equipped with the upright AxioImager.M2
stand (Zeiss), running ZEN 2010 software. Images were
deconvoluted using Huygens software (4.2.2 p0) and visualized
with ImageJ (NIH).
1http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
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FIGURE 1 | Nested PCR analysis of bacterial DNA extracted from patients with ALS. PCR analysis was carried out as described in section Materials and Methods.
(A) Schematic representation of bacterial rRNA genes (16S and 23S) and the intergenic sequence (IGS) region, including the location of the primers employed for the
different reactions. (B) Agarose gel electrophoresis of the DNA fragments amplified by nested PCR; analysis of three CNS regions (MC, MD, and SC) from 11
patients amplifying the IGS region Primers 1406(F) – 559(R) and 1492 (F) –242 (R) were used in the first and second round PCR, respectively, C-, control PCR
without DNA; CE, control of DNA extraction without DNA; MC, motor cortex; MD, medulla; SC, spinal cord; SC1, SC2, and SC3, three samples from different
regions of the spinal cord.
RESULTS
Detection of Bacterial DNA in CNS
Tissue by Nested PCR
Recent evidence from several laboratories has revealed that
bacteria can be detected in brain tissue from ostensibly healthy
subjects, albeit at low levels (Branton et al., 2016; Emery et al.,
2017; Alonso et al., 2018). Moreover, we and others have recently
identified bacteria in the CNS of patients diagnosed with multiple
sclerosis (MS) and Alzheimer’s disease (AD) (Branton et al., 2016;
Emery et al., 2017; Pisa et al., 2017; Alonso et al., 2018). To test
whether bacteria are present in the CNS tissue from patients with
ALS, we analyzed DNA isolated from frozen postmortem tissue
of the following CNS regions from 11 patients: motor cortex
(MC), median bulb (medulla, MD) and spinal cord (SC). Three
different regions of the SC are indicated as SC1, SC2, and SC3.
As the bulk of this DNA is human, we used nested PCR to
enhance the detection of bacterial DNA using primers directed
to the IGS region between ribosomal RNA (rRNA) genes (see
schematic in Figure 1A). As negative controls, we performed
PCR without DNA and without extraction. Results showed that
several DNA fragments were amplified in virtually all regions
from the 11 patients, but not in the negative controls (Figure 1B).
We next extracted and sequenced the individual DNA bands to
identify the bacterial species. The most representative species
was Cutibacterium acnes (formerly known as Propionibacterium
acnes) (band size 402–568 bp). This bacterium has been reported
in previous studies in human CNS (Emery et al., 2017; Alonso
et al., 2018). Other species detected included Corynebacterium sp
(patient ALS5, SC) (band size 630 bp), Fusobacterium nucleatum
(ALS11, SC) (band size 460 bp), Lawsonella clevelandesis (ALS9,
SC) (band size 540 bp) and Streptococcus thermophilus (ALS8,
MD) (band size 488bp). As a complementary approach, we
also performed nested PCR of the V3–V4 region of the 16S
rRNA gene, which in this case amplified a, similarly, sized
DNA fragment (400 bp) in all patients except patient ALS10
(Supplementary Figure 1). Sequencing of the extracted DNA
showed that the amplified product corresponded to Burkholderia
species (Supplementary Table 1). These results show that
bacterial species are present in the CNS tissue from patients with
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ALS, and some species are preferentially amplified depending
on the primers employed. All dises sequences are publically
available at ENA.
Detection of Bacterial DNA From ALS
Patients by NGS
We next used NGS to comprehensively analyze the DNA samples
from the different CNS regions of the 11 patients. Accordingly,
an internal region of the 16S rRNA gene was amplified and
sequenced on the Illumina Platform. The number of sequences
obtained for each sample varied from 140,818 to 238,088. The
bacterial species detected are listed in Supplementary Table 2,
with only those with a presentation> 1% shown. In concordance
with previous reports, a great variety of species were identified
using this technique. The order Sphyngomonodales, the family
Methilobacteriaceae and the genus Cupriavidus seemed to be the
most prevalent bacterial groups in ALS patients. Interestingly,
Sphyngomonodales has not previously been reported in the CNS
of control subjects (Branton et al., 2016; Emery et al., 2017;
Alonso et al., 2018). The bacterial phyla and orders from the three
CNS regions (MC, MD and SC) of the ALS patients are shown
in Figure 2. The phyla Actinobacteria and Proteobacteria were
found in all three regions of the 11 ALS patients analyzed. The
phyla Firmicutes and Bacteriodetes were also prevalent, whereas
other phyla were less represented. For example, Fusobacteria was
found in only one patient, in all three CNS regions. In addition,
we detected a great variability in the bacterial orders present
in ALS patients. For instance, Actinomycetales, Burkholderiales
and Rhizobiales were detected in all ALS patients, whereas
Xanthomonadales was found only in two patients (ALS6, MD and
ALS7, SC3). These findings reveal the irregular range of bacteria
in the different samples tested, indicating that these bacteria
are likely not due to contamination during DNA extraction
and NGS analysis.
Principal Component Analysis
Multivariate PCA of the results obtained from the three CNS
regions in ALS patients is shown in Figure 3A. The distribution
of bacterial species was similar between the three regions, and
statistical analysis using the Wilconxon–Mann–Whitney test
showed that there were no significant differences between each
CNS region (p> 0.05).
The PCA of the present NGS data set was next compared
with that previously reported for patients with AD and control
subjects (Alonso et al., 2018). The distribution between ALS
and AD patients was similar (Figure 3B), however, when the
comparison was made between each region from ALS patients
and the enthorrinal region from AD patients, the distribution
was significantly different (Figures 4A–C). These findings were
supported by White’s nonparametric t-test with p-values adjusted
for multiple testing using the Benjamini–Hochberg approach
in STAMP (Supplementary Figure 2), showing the genera-
and species-dependent significant differences. For instance,
the bacterial genera Acrobacter, Thermomonas, Hemophylus,
Propionibacterium, and Corynebacterium are more represented
in MC, MD, and SC regions in ALS patients than in AD patients.
Further, Propionibacterium acnes is the most representative in
each region with respect to AD patients.
Finally, we extended this analysis to compare ALS patients
with control subjects (Figure 5). Results indicated that there
was a small difference in distribution between each region from
ALS patients and the control subjects. Only one control (C9)
was not in the clustered group. These observations were also
supported by the statistical analysis, and we conclude that all
ALS samples (MC, MD, and SC) are significantly different from
the control group.
Detection of Bacteria in CNS Tissue by
Immunohistochemistry
To complement the bacterial DNA study, we performed
immunohistochemistry to directly test for prokaryotic structures
in the CNS of ALS patients. Initially, we performed double
immunofluorescence analysis using two different antibodies:
a mouse monoclonal antibody against bacterial peptidoglycan
(shown in green), and a rabbit polyclonal antibody against
Candida albicans (shown in red) (Figure 6). Several prokaryotic
morphologies could be detected in different CNS regions by
confocal microscopy. For example, a bacilliform structure of
4–7 µm in size was recognized with the anti-peptidoglycan
antibody (Figures 6V,X). Smaller bacilli of 1–2 µm were
also immunostained with this antibody in some sections
(Figures 6B,G). These bacilli are clearly differentiated from yeast-
like structures that were recognized with the anti-C. albicans
antibody (see for instance Figure 6K). In addition to these
prokaryotic morphologies, a variety of immunopositive microbial
structures were detected, in good agreement with our recent
study (Alonso et al., 2017b). Some of these microbial cells
were clearly intranuclear (Supplementary Figure 3). Different
bacilli-like morphologies that stained with the anti-peptidoglycan
antibody could also be clearly seen. The range in sizes of
these structures suggests that they represent different species.
Moreover, yeast-like cells and some hyphae were also evident.
Most likely, the structures immunostained with the anti-
peptidoglycan antibody are prokaryotic in origin, although the
anti-C. albicans antibody not only cross-reacts with several
fungal species, but also with some bacteria (Pisa et al., 2017).
Nevertheless, none of these antibodies recognizes human cells.
We also immunostained the samples with a rabbit polyclonal
antibody against Chlamydophila pneumoniae (shown in green)
and with a rat polyclonal antibody raised against the fungus
Trichoderma viride (shown in red) (Figure 7). It must be
taken into consideration that these two antibodies can cross-
react with prokaryotic and yeast-like cells (Pisa et al., 2017).
Both the anti-C. pneumoniae antibody and the anti-T. viride
antibody recognize a variety of bacteria and also immunoreact
with several yeast species. However, the spectrum of species
recognized by both antibodies is different. Notably, this
double immunofluorescence analysis also revealed a number of
microbial structures (Figure 7). In some instances, small rounded
prokaryotic-like cells were evidenced (see Figures 7C,P). On
other occasions, larger rounded cells or even elongated structures
were detected (Figures 7A,B,J–M).
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FIGURE 2 | Distribution of bacteria phyla and orders obtained by NGS of DNA from eleven ALS patients. Computational analyses of the sequences obtained on the
Illumina platform using Qiime classified the data into bacteria phyla and orders. (A) Panels show the results of bacteria phyla obtained from three CNS regions. (B)
Panels show the results of bacteria orders obtained from three CNS regions. SC1, SC2 and SC3, three samples from different regions of the spinal cord.
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FIGURE 3 | Principal component analysis of bacteria of CNS regions from ALS patients and AD patients. (A) Three-dimensional (3D) principal component analysis
(PCA) between different CNS regions from 11 ALS patients. (B) 3D PCA between ALS and AD patients. MC, motor cortex; MD, medulla; SC, spinal cord, SC1, SC2,
and SC3, three samples from different regions of the spinal cord.
In conclusion, a variety of prokaryotic-like structures can be
revealed using immunohistochemistry analysis of CNS sections
from patients with ALS. These findings are consistent with the
results found with PCR and NGS, demonstrating the existence of
a variety of bacterial species.
Detection of Corpora Amylacea by
Immunohistochemistry
Corpora amylacea (CA) are small (10–50 µm) basophilic bodies
that have been identified in several neurodegenerative diseases
including AD and Parkinson’s disease (Pisa et al., 2016a). By
proteomic analysis, we recently demonstrated that in addition to
human proteins, CA purified from brain tissue of patients with
AD contain fungal and bacterial proteins (Pisa et al., 2018). We
next examined for CA in ALS patients, and whether they stained
positive with anti-peptidoglycan or anti-C. albicans antibodies.
CA were found in several tissue sections from different ALS
patients, and a clear immunostaining with anti-peptidoglycan
antibodies (green) was observed in many of these CA (Figure 8).
In some instances, immunoreactivity of CA with a C. albicans
antibody (red) was also observed (Figures 8C,E,O). This result
is consistent with the concept that CA contain both fungal and
bacterial macromolecules and their function might be to collect
the cellular and microbial debris provoked by infections in the
brain (Pisa et al., 2018). Since CA are generated over long time
periods (months or even years), these microbial proteins were
likely sequestered in CA when the patients were alive.
Analysis of the Exanucleotide Expansion
Repeat in C9orf72
About 10% of ALS cases contain a repeated expansion in
C9orf72, which has also been found in patients with several
neuropathological diseases and in control subjects (Woollacott
and Mead, 2014). Our next goal was to test for this
repeated expansion in the ALS patients studied in this work.
We performed PCR analysis in the MC and MD regions of the
11 ALS patients, since somatic variations of this repeat expansion
could exist. Results of the amplification and sequencing are listed
in Supplementary Table 3. We found three GGGGCC repeats in
most patients (ALS1–7 and ALS9), whereas only two repeats were
found in two patients (ALS10, MC and ALS11, MC). For each
patient the repeat was the same in the two CNS region tested.
Thus, the number of repeats is far below that required to cause
pathogenicity (above 30 repeats) (Cleary et al., 2016).
DISCUSSION
Research on the etiology of ALS suggests that this disease
has a genetic component. Particularly, the possibility that a
hexanucleotide repeat expansion in C9orf72 is responsible for
ALS has been put forward (Corcia et al., 2017). The rationale
behind this proposal is that the synthesis of aberrantly spliced
mRNA retaining intron 1 bearing the repeat expansion can
interact and sequester some crucial RBPs (Ciesiolka et al., 2017).
In addition, protein synthesis directed by this repeat expansion
can lead to the production of aberrant peptides (Ash et al., 2013).
Both mechanisms would be detrimental for cell viability. The
synthesis of aberrant peptides would induce the formation of
peptide aggregates in the cytoplasm and the nucleus leading to
cell death (Iguchi et al., 2013; Saberi et al., 2015; Huynh et al.,
2016; Kumar and Ghosh, 2017; Tabet et al., 2018). However,
this does not apply to the bulk of ALS cases, since this repeat
expansion is infrequent in non-Caucasian patients, and is not
found in about 90% of ALS patients of European ancestry
(Renton et al., 2014). Curiously, the repeat expansion has also
been found in a number of patients with other neurological
diseases including AD and PD. Moreover, intermediate numbers
of the repeat expansion have also been found in healthy control
subjects (Woollacott and Mead, 2014). Thus, it could be possible
that this repeat expansion predisposes to neurological diseases.
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FIGURE 4 | Three- and two-dimensional principal component analysis of bacteria of CNS regions from ALS patients and AD patients. Comparison of three separate
CNS regions between AD and ALS patients. (A) Left panel: three-dimensional (3D) principal component analysis (PCA) between MC regions of ten ALS patients
(plots in red) and 10 AD patients (plots in blue). Right panel: 2D PCA. (B) Left panel: 3D PCA between MD regions of eleven ALS patients (plots in blue) and ten AD
patients (plots in red). Right panel: 2D PCA. (C) Left panel: 3D PCA between SC regions of 11 ALS patients (plots in blue) and 10 AD patients (plots in red). Right
panel: 2D PCA. The UniFrac method was used to calculate this parameter. MC, motor cortex; MD, medulla; SC, spinal cord.
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FIGURE 5 | Three- and two-dimensional principal component analysis of bacteria of CNS regions from ALS patients and control samples. (A) Left panel:
three-dimensional (3D) principal component analysis (PCA) between MC regions of 10 ALS patients (plots in blue) and 9 control samples (plots in red). Right panel:
2D PCA. (B) Left panel: 3D principal component analysis between MD regions from 11 ALS patients (plots in blue) and 9 control samples (plots in red). Right panel:
2D PCA. (C) Left panel: 3D PCA between SC regions from 11 ALS patients (plots in blue) and 9 control samples (plots in red). Right panel: 2D PCA. The UniFrac
method was used to calculate this parameter. MC, motor cortex; MD, medulla; SC, spinal cord.
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FIGURE 6 | Immunohistochemistry to detect peptidoglycan in brain tissue from ALS patients. Double immunostaining and confocal microscopy were carried out as
indicated in section Materials and Methods. CNS sections were immunostained with a mouse monoclonal anti-peptidoglycan antibody (green) (1:20 dilution) and a
rabbit polyclonal anti-C. albicans antibody (red) (1:500 dilution). DAPI staining of nuclei appears in blue. Scale bar: 5 µm. (A–C) ALS2; (D–F) ALS3; (G–I) ALS4; (J,K)
ALS5; (L–N) ALS6; (O) ALS1; (P) ALS7; (Q,R) ALS8; (S) ALS9; (T–V) ALS10; and (W,X) ALS11. (A,D,G,J,L,Q,S,T,W) MC section; (B,E,H,K,M,O,U,X) MD section;
and (C,F,I,N,P,R,V) SC section.
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FIGURE 7 | Immunohistochemistry to detect C. pneumoniae antigens in brain tissue from ALS patients. Double immunostaining and confocal microscopy were
carried out as indicated in section Materials and Methods. CNS sections were immunostained with a rabbit polyclonal C. pneumoniae antibody (green) (1:20 dilution)
and a rat polyclonal anti-T. viride antibody (red) (1:20 dilution). DAPI staining of nuclei appears in blue. Scale bar: 5 µm. (A,B) ALS2; (C,D) ALS3; (E) ALS5; (F–H)
ALS6; (I,J) ALS1; (K) ALS7; (L,M) ALS8; (N) ALS9; (O) ALS10; and (P) ALS11. (A,C,F,I,K,L,P) MC section; (G,N,O) MD section; and (B,D,E,H,J,M) SC section.
In this sense, its toxic effect on cellular physiology might
influence the acquisition of microbial infections. In fact, the
transcriptome in neural tissue of ALS cases indicates alterations
in mRNA transcripts involved in the immune response
(Prudencio et al., 2015).
We have advanced the concept that microbial infection
contributes to the pathology of ALS, based on the demonstration
that fungal proteins and DNA can be detected in the CSF and
in the CNS of ALS patients (Alonso et al., 2015). Furthermore,
the direct visualization of yeast-like cells and hyphae provides
compelling evidence that fungal infection is present in different
CNS regions (Alonso et al., 2017b). These fungal structures were
present in all ALS patients analyzed and the species present
in the CNS were precisely identified by NGS, rendering the
genera Candida, Malassezia, Fusarium, Botrytis, Trichoderma,
and Cryptococcus as those most prominent in ALS patients.
Our present findings indicate that in addition to mycoses,
bacterial infection can coexist in neural tissue pointing to the
existence of polymicrobial infections in the CNS of these patients.
We used both nested PCR and NGS assays to perform an
exhaustive analysis of prokaryotic microbes that colonize the
CNS of ALS patients, revealing a great variety of bacterial species.
Thus, we now have a general idea about the microbiota, both
fungal and bacterial, which exists in the CNS of ALS.
The concept that the etiology of ALS is microbial in origin
can go some way to explain all of the findings reported for
the neuropathology of this disease. First, microbial infection
is consistent with neuroinflammation in ALS, with a clear
infiltration of T lymphocytes (Henkel et al., 2004; Hooten et al.,
2015; Ransohoff, 2016). In fact, mycoses would lead to the
infiltration of immune cells into neural tissues, and the decrease
in Th2 lymphocytes correlates with the rapid progression of
the disease (Henkel et al., 2013). Second, the high levels of
chitinase found in the CSF of ALS patients could be due to
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FIGURE 8 | Bacterial proteins in corpora amylacea from ALS patients. Double immunostaining and confocal microscopy were carried out as indicated in section
Materials and Methods. CNS sections were immunostained with a mouse monoclonal anti-peptidoglycan antibody (green) (1:20 dilution) and a rabbit polyclonal
anti-C. albicans antibody (red) (1:500 dilution). DAPI staining of nuclei appears in blue. Scale bar: 25 µm. (A,B) ALS2; (C) ALS3; (D,E), ALS4; (F) ALS5; (G,H) ALS7;
(I,J) ALS8; (K) ALS9; (L–N) ALS10; and (O) ALS11. (A,D,F,L) MC section; (G,I,K,M) MD section; and (B,C,E,H,J,N,O) SC section.
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the presence of fungal chitin, which induces the synthesis of
chitinase (Varghese et al., 2013b; Pagliardini et al., 2015). Third,
the acquisition of microbial infections is consistent with the
sudden appearance of the disease after several decades of life.
Moreover, the focal presentation of ALS, followed by its spread
to other neighboring CNS areas, can be clearly explained if ALS
is caused by polymicrobial infections. Fourth, infection could
trigger a stress response in neural cells, blocking the shuttling
of proteins between the nucleus and cytoplasm and leading to
the formation of stress granules and cell death. Fifth, it is well
established that the genetic background of a given individual
also affects the susceptibility to microbial infection (Carvalho
et al., 2010; Glocker and Grimbacher, 2010; Ok et al., 2011;
Maskarinec et al., 2016). Thus, the genetic predisposition for
ALS could reflect the susceptibility for microbial colonization.
Strengthening this concept, the first mutated gene discovered
in familial ALS was SOD1, which forms part of the innate
immune response and is crucial for host defense against microbes
(Moisse and Strong, 2006; Lionakis, 2014). Therefore, to the
best of our knowledge, none of the known pathological events
of ALS discard the possibility that this disease is caused
by polymicrobial infections.
By contrast, none of the other hypotheses put forward to
account for the pathology of ALS is sufficiently robust to provide
a logical explanation for all of the described observations. In
particular, the induction of chitinase and the neuroinflammation
with infiltrates of immune cells cannot be explained by defects
in protein transport between the nucleus and cytoplasm. Further,
since C9orf72 is ubiquitously expressed in human tissues,
leading to aberrant proteins from very early in development,
why does the toxicity and clinical symptoms of ALS manifest
decades after birth?
Another consideration of interest is the presence of amyloid
deposits in ALS, as occurs in other neurodegenerative diseases
(Schmidt et al., 1998; Farid et al., 2015; Takeda, 2018). Amyloid
peptide exhibits strong antifungal and antibacterial activity and
forms part of the innate immune response (Soscia et al., 2010;
Kumar et al., 2016). Accordingly, microbial infections would
stimulate the immune response and trigger the synthesis of
amyloid peptide. The fact that there are large differences in
the severity of clinical symptoms between patients with ALS,
which are reflected in the survival time after diagnosis, is also
consistent with the idea that mixed microbial infections – which
vary from patient to patient – are responsible for the disease.
Moreover, the overlapping clinical symptoms between several
neurodegenerative diseases are also in good agreement with
the hypothesis that they can be caused by a variety of mixed
infections. Indeed, we have provided evidence that both fungal
and bacteria colonize different CNS regions in AD (Alonso
et al., 2017a, 2018; Pisa et al., 2017). The confirmation that
these diseases are caused by fungi or bacteria, or both, should
come from clinical trials using already approved antifungal
and antibacterial agents. Patients with these neurodegene-
rative diseases do not have to wait for the development of
new therapeutic agents. These studies using safe antimicrobial
compounds could be started immediately after approval
of these trials.
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